Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, reflects on toxicities associated with idecabtagene vicleucel (ide-cel) in multiple myeloma including neurotoxicity, cytokine release syndrome (CRS) and cytopenias. Dr Hansen highlights strategies employed to mitigate the incidence of treatment-related adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.